Janux Therapeutics, Inc.
JANX
$23.64
$0.632.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.86M | -23.51M | -20.22M | -28.06M | -5.96M |
| Total Depreciation and Amortization | 541.00K | 519.00K | 512.00K | 510.00K | 506.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.75M | 6.48M | 3.32M | 12.49M | 2.78M |
| Change in Net Operating Assets | 3.75M | -516.00K | -345.00K | 12.83M | -7.35M |
| Cash from Operations | -23.81M | -17.02M | -16.73M | -2.23M | -10.02M |
| Capital Expenditure | -473.00K | -371.00K | -42.00K | -25.00K | -95.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.04M | -340.02M | 33.97M | 12.70M | -190.79M |
| Cash from Investing | 1.56M | -340.39M | 33.93M | 12.67M | -190.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 954.00K | 901.00K | 386.65M | 1.65M | 2.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -347.00K | -- | -- | -- |
| Cash from Financing | 954.00K | 554.00K | 386.65M | 1.65M | 2.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.30M | -356.86M | 403.85M | 12.09M | -198.14M |